Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share
This article was originally published in The Pink Sheet Daily
Executive Summary
Marketing of patented and branded drugs is a relatively new concept in India but going by the initial strategies put into play by multinational companies it has all the ingredients of blowing up into an all-out war in the race to capture the mind recall of doctors prescribing anti-diabetics.
You may also be interested in...
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin
Merck Vows To Be In Top Five In India By 2015; Push Will Come From 13 New Launches In The Next Two Years
MUMBAI - Buoyed by strong performance of its key brands Januvia (sitagliptin) and Gardasil launched last year in India, U.S. drug giant Merck is going full throttle in its ambition to figure in the top five companies in India by 2015